MAPT and Alzheimer disease: Considering the CSF levels of p-tau and t-tau as biomarkers of neurodegeneration and AD progression [50], our findings suggest that isoprostanes (8,12-iso-iPF2α VI, 5-iPF2 α Vi) may increase during the prodromal phase of AD development independent of APOE ε4.